Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial

Innovent’s anti-VEGF drug held its own against Regeneron and Bayer’s blockbuster eye disease therapy Eylea in a phase 2 trial.

The study saw 132 participants with neovascular age-related macular degeneration (nAMD) randomized to receive either 6.4 mg or 8 mg doses of Innovent’s IBI302 or 2 mg of Eylea. Individuals on Eylea received their treatment every eight weeks, while those receiving IBI302 received treatment either every eight or 12 weeks depending on how they had responded to a loading therapy.